why Ginkgo Bioworks Holdings Inc. [DNA] is a Good Choice for Investors After New Price Target of $8.43


Ginkgo Bioworks Holdings Inc. [NYSE: DNA] jumped around 0.18 points on Friday, while shares priced at $3.66 at the close of the session, up 5.17%. The company report on June 2, 2022 that Ginkgo Bioworks Announces Participation in William Blair’s 42nd Annual Growth Stock Conference.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that management is scheduled to participate in William Blair’s 42nd Annual Growth Stock Conference, on June 9, 2022, at 11:20 a.m. CT.

Further details, a webcast link, and a replay of the presentation, if available, will be posted on the company’s investor relations website at https://investors.ginkgobioworks.com/events.

Ginkgo Bioworks Holdings Inc. stock is now -55.96% down from its year-to-date (YTD) trading value. DNA Stock saw the intraday high of $3.68 and lowest of $3.29 per share. The company’s 52-week high price is 15.86, which means current price is +75.12% above from all time high which was touched on 01/03/22.

Compared to the average trading volume of 22.56M shares, DNA reached a trading volume of 22581156 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Ginkgo Bioworks Holdings Inc. [DNA]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for DNA shares is $8.43 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on DNA stock is a recommendation set at 1.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

BofA Securities have made an estimate for Ginkgo Bioworks Holdings Inc. shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on May 18, 2022. While these analysts kept the previous recommendation, Cowen raised their target price to Outperform. The new note on the price target was released on March 02, 2022, representing the official price target for Ginkgo Bioworks Holdings Inc. stock. Previously, the target price had yet another raise to $7, while Goldman analysts kept a Neutral rating on DNA stock.

The Average True Range (ATR) for Ginkgo Bioworks Holdings Inc. is set at 0.35, with the Price to Sales ratio for DNA stock in the period of the last 12 months amounting to 10.74. The Price to Book ratio for the last quarter was 3.73, with the Price to Cash per share for the same quarter was set at 1.05.

How has DNA stock performed recently?

Ginkgo Bioworks Holdings Inc. [DNA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 23.65. With this latest performance, DNA shares gained by 11.25% in over the last four-week period, additionally sinking by -64.19% over the last 6 months – not to mention a drop of -62.92% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DNA stock in for the last two-week period is set at 61.97, with the RSI for the last a single of trading hit 69.83, and the three-weeks RSI is set at 56.51 for Ginkgo Bioworks Holdings Inc. [DNA]. The present Moving Average for the last 50 days of trading for this stock 3.27, while it was recorded at 3.28 for the last single week of trading, and 7.61 for the last 200 days.

Ginkgo Bioworks Holdings Inc. [DNA]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Ginkgo Bioworks Holdings Inc. [DNA] shares currently have an operating margin of -582.43 and a Gross Margin at +53.93. Ginkgo Bioworks Holdings Inc.’s Net Margin is presently recorded at -583.12.

Return on Equity for this stock declined to -243.13, with Return on Assets sitting at -176.62.

Ginkgo Bioworks Holdings Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 10.70 and a Current Ratio set at 10.70.

Insider trade positions for Ginkgo Bioworks Holdings Inc. [DNA]

There are presently around $2,435 million, or 75.40% of DNA stock, in the hands of institutional investors. The top three institutional holders of DNA stocks are: BAILLIE GIFFORD & CO with ownership of 167,752,680, which is approximately 53.269% of the company’s market cap and around 0.40% of the total institutional ownership; GENERAL ATLANTIC, L.P., holding 90,810,814 shares of the stock with an approximate value of $332.37 million in DNA stocks shares; and ANCHORAGE CAPITAL GROUP, L.L.C., currently with $253.12 million in DNA stock with ownership of nearly 0% of the company’s market capitalization.

Positions in Ginkgo Bioworks Holdings Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 133 institutional holders increased their position in Ginkgo Bioworks Holdings Inc. [NYSE:DNA] by around 135,509,635 shares. Additionally, 76 investors decreased positions by around 367,326,835 shares, while 23 investors held positions by with 162,343,483 shares. The mentioned changes placed institutional holdings at 665,179,953 shares, according to the latest SEC report filing. DNA stock had 70 new institutional investments in for a total of 18,452,679 shares, while 44 institutional investors sold positions of 22,802,276 shares during the same period.